Advertisement

Topics

FDA grants Priority Review for Lynparza in metastatic breast cancer

10:57 EDT 18 Oct 2017 | CentreWatch

AstraZeneca and Merck, known as MSD outside the U.S. and Canada, announced that the FDA has accepted and granted priority review for a supplemental New Drug Application (sNDA) for the use of Lynparza (olaparib) tablets in patients with germline BRCA-mutated (gBRCA), HER2-negative metastatic breast cancer (MBC) who have been previously treated with chemotherapy either in the neoadjuvant, adjuvant […]

The post FDA grants Priority Review for Lynparza in metastatic breast cancer appeared first on CenterWatch News Online.

Original Article: FDA grants Priority Review for Lynparza in metastatic breast cancer

NEXT ARTICLE

More From BioPortfolio on "FDA grants Priority Review for Lynparza in metastatic breast cancer"

Quick Search
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Merck and Co
Merck & Co is the 7th largest pharmaceutical company in the world based on annual sales, which reached $25,236m in 2009. They have developed 14 vaccines and over 40 prescription products in the major therapeutic areas of cardiovascular disease, respi...